Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Tóm tắt
Từ khóa
Tài liệu tham khảo
Fridkin, 2005, The changing face of fungal infections in health care settings, Clin Infect Dis, 41, 1455, 10.1086/497138
Pappas, 2003, A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients, Clin Infect Dis, 37, 634, 10.1086/376906
Tortorano, 2004, Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study, Eur J Clin Microbiol Infect Dis, 23, 317, 10.1007/s10096-004-1103-y
Trick, 2002, Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999, Clin Infect Dis, 35, 627, 10.1086/342300
Wisplinghoff, 2004, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, 309, 10.1086/421946
Marr, 2000, Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole, J Infect Dis, 181, 309, 10.1086/315193
Viscoli, 1999, Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC), Clin Infect Dis, 28, 1071, 10.1086/514731
Marchetti, 2004, Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000, Clin Infect Dis, 38, 311, 10.1086/380637
Arendrup, 2005, Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility, J Clin Microbiol, 43, 4434, 10.1128/JCM.43.9.4434-4440.2005
Richet, 2002, Candidemia in French hospitals: incidence rates and characteristics, Clin Microbiol Infect, 8, 405, 10.1046/j.1469-0691.2002.00446.x
Gudlaugsson, 2003, Attributable mortality of nosocomial candidemia, revisited, Clin Infect Dis, 37, 1172, 10.1086/378745
Zaoutis, 2005, The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis, Clin Infect Dis, 41, 1232, 10.1086/496922
Morgan, 2005, Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance, Infect Control Hosp Epidemiol, 26, 540, 10.1086/502581
Field, 1990, Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, Clinical Practice Guidelines: Directions for a New Program, 10.17226/1626
Canadian Task Force on the Periodic Health Examination, 1979, The periodic health examination, Can Med Assoc J, 121, 1193
Linden, 1999, Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections, Pharmacotherapy, 19, 1261, 10.1592/phco.19.16.1261.30870
Walsh, 1997, Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis, Antimicrob Agents Chemother, 41, 1944, 10.1128/AAC.41.9.1944
Deray, 2002, Amphotericin B nephrotoxicity, J Antimicrob Chemother, 49, 37, 10.1093/jac/49.suppl_1.37
Bowden, 1996, Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant, J Infect Dis, 173, 1208, 10.1093/infdis/173.5.1208
Walsh, 1998, Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases, Clin Infect Dis, 26, 1383, 10.1086/516353
Wingard, 2002, Lipid formulations of amphotericins: are you a lumper or a splitter?, Clin Infect Dis, 35, 891, 10.1086/342563
Agustin, 1999, Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases, Clin Infect Dis, 29, 686, 10.1086/598658
Groll, 2000, Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system, J Infect Dis, 182, 274, 10.1086/315643
Bates, 2001, Mortality and costs of acute renal failure associated with amphotericin B therapy, Clin Infect Dis, 32, 686, 10.1086/319211
Pfaller, 2006, Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing, Clin Microbiol Rev, 19, 435, 10.1128/CMR.19.2.435-447.2006
Espinel-Ingroff, 2005, International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole, J Clin Microbiol, 43, 3884, 10.1128/JCM.43.8.3884-3889.2005
Rex, 1994, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute, N Engl J Med, 331, 1325, 10.1056/NEJM199411173312001
Rex, 2003, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects, Clin Infect Dis, 36, 1221, 10.1086/374850
Sobel, 2001, Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole, Am J Obstet Gynecol, 185, 363, 10.1067/mob.2001.115116
Goldman, 2005, A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40, Clin Infect Dis, 41, 1473, 10.1086/497373
Arndt, 1988, Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system, J Infect Dis, 157, 178, 10.1093/infdis/157.1.178
Eichel, 1996, Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis, Mycoses, 39, 102, 10.1111/j.1439-0507.1996.tb00514.x
Lange, 1997, Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers, J Clin Pharmacol, 37, 535, 10.1002/j.1552-4604.1997.tb04332.x
Van Peer, 1989, The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects, Eur J Clin Pharmacol, 36, 423, 10.1007/BF00558308
Hariprasad, 2004, Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans, Arch Ophthalmol, 122, 42, 10.1001/archopht.122.1.42
Lutsar, 2003, Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients, Clin Infect Dis, 37, 728, 10.1086/377131
Leveque, 2006, Clinical pharmacokinetics of voriconazole, Int J Antimicrob Agents, 27, 274, 10.1016/j.ijantimicag.2006.01.003
von Mach, 2006, Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy, BMC Clin Pharmacol, 6, 6, 10.1186/1472-6904-6-6
Smith, 2006, Voriconazole therapeutic drug monitoring, Antimicrob Agents Chemother, 50, 1570, 10.1128/AAC.50.4.1570-1572.2006
Ikeda, 2004, Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status, Clin Pharmacol Ther, 75, 587, 10.1016/j.clpt.2004.02.002
Courtney, 2003, Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults, Antimicrob Agents Chemother, 47, 2788, 10.1128/AAC.47.9.2788-2795.2003
Walsh, 2002, Echinocandins—an advance in the primary treatment of invasive candidiasis, N Engl J Med, 347, 2070, 10.1056/NEJMe020142
Bennett, 2006, Echinocandins for candidemia in adults without neutropenia, N Engl J Med, 355, 1154, 10.1056/NEJMct060052
Villanueva, 2001, A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis, Clin Infect Dis, 33, 1529, 10.1086/323401
Villanueva, 2002, A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis, Am J Med, 113, 294, 10.1016/S0002-9343(02)01191-9
de Wet, 2004, A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients, Clin Infect Dis, 39, 842, 10.1086/423377
Krause, 2004, A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis, Clin Infect Dis, 39, 770, 10.1086/423378
Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med, 347, 2020, 10.1056/NEJMoa021585
Kuse, 2007, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial, Lancet, 369, 1519, 10.1016/S0140-6736(07)60605-9
Reboli, 2007, Anidulafungin versus fluconazole for invasive candidiasis, N Engl J Med, 356, 2472, 10.1056/NEJMoa066906
Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis, 45, 883, 10.1086/520980
Schonebeck, 1973, Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function, Chemotherapy, 18, 321, 10.1159/000221279
Stamm, 1987, Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis, Am J Med, 83, 236, 10.1016/0002-9343(87)90691-7
Groll, 1998, Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development, Adv Pharmacol, 44, 343, 10.1016/S1054-3589(08)60129-5
Steinbach, 2005, Antifungal agents in children, Pediatr Clin North Am, 52, 895, 10.1016/j.pcl.2005.02.009
van den Anker, 1995, Antifungal agents in neonatal systemic candidiasis, Antimicrob Agents Chemother, 39, 1391, 10.1128/AAC.39.7.1391
Juster-Reicher, 2000, Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants, Infection, 28, 223, 10.1007/s150100070040
Baley, 1990, Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates, J Pediatr, 116, 791, 10.1016/S0022-3476(05)82674-5
Lee, 1992, Safety and pharmacokinetics of fluconazole in children with neoplastic diseases, J Pediatr, 120, 987, 10.1016/S0022-3476(05)81975-4
Saxen, 1993, Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life, Clin Pharmacol Ther, 54, 269, 10.1038/clpt.1993.147
Seay, 1995, Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases, Pharmacotherapy, 15, 52, 10.1002/j.1875-9114.1995.tb04331.x
Wade, 2008, Population pharmacokinetics of fluconazole in young infants, Antimicrob Agents Chemother, 52, 4043, 10.1128/AAC.00569-08
de Repentigny, 1998, Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children, Antimicrob Agents Chemother, 42, 404, 10.1128/AAC.42.2.404
Groll, 2002, Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis, Antimicrob Agents Chemother, 46, 2554, 10.1128/AAC.46.8.2554-2563.2002
Walsh, 2004, Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration, Antimicrob Agents Chemother, 48, 2166, 10.1128/AAC.48.6.2166-2172.2004
Steinbach, 2005, New antifungal agents under development in children and neonates, Curr Opin Infect Dis, 18, 484, 10.1097/01.qco.0000185986.64759.9a
Seibel, 2005, Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients, Antimicrob Agents Chemother, 49, 3317, 10.1128/AAC.49.8.3317-3324.2005
Heresi, 2006, The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants, Pediatr Infect Dis J, 25, 1110, 10.1097/01.inf.0000245103.07614.e1
Benjamin, 2006, Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections, Antimicrob Agents Chemother, 50, 632, 10.1128/AAC.50.2.632-638.2006
Smith, Pharmacokinetics of an elevated dosage of micafungin in premature neonates, Ped Infect Dis J
Moudgal, 2003, Antifungal drugs in pregnancy: a review, Expert Opin Drug Saf, 2, 475, 10.1517/14740338.2.5.475
Pascual, 2008, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin Infect Dis, 46, 201, 10.1086/524669
Clinical and Laboratory Standards Institute (CLSI), 2008, Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard, CLSI document M27-A3, 3rd
Morrell, 2005, Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality, Antimicrob Agents Chemother, 49, 3640, 10.1128/AAC.49.9.3640-3645.2005
Garey, 2006, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study, Clin Infect Dis, 43, 25, 10.1086/504810
Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial, Lancet, 366, 1435, 10.1016/S0140-6736(05)67490-9
Wiederhold, 2003, The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy, Expert Opin Investig Drugs, 12, 1313, 10.1517/13543784.12.8.1313
Pfaller, 2007, Epidemiology of invasive candidiasis: a persistent public health problem, Clin Microbiol Rev, 20, 133, 10.1128/CMR.00029-06
Nguyen, 1995, Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study, Arch Intern Med, 155, 2429, 10.1001/archinte.1995.00430220087009
Rex, 1995, Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group, Clin Infect Dis, 21, 994, 10.1093/clinids/21.4.994
Luzzati, 2000, Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital, Eur J Clin Microbiol Infect Dis, 19, 602, 10.1007/s100960000325
Karlowicz, 2000, Should central venous catheters be removed as soon as candidemia is detected in neonates?, Pediatrics, 106, 63, 10.1542/peds.106.5.e63
Nucci, 2001, Revisiting the source. of candidemia: skin or gut?, Clin Infect Dis, 33, 1959, 10.1086/323759
Anaissie, 1998, Predictors of adverse outcome in cancer patients with candidemia, Am J Med, 104, 238, 10.1016/S0002-9343(98)00030-8
Anaissie, 1996, Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study, Am J Med, 101, 170, 10.1016/S0002-9343(96)80072-6
Betts, 2006, Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients, Cancer, 106, 466, 10.1002/cncr.21615
Walsh, 1999, Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group, N Engl J Med, 340, 764, 10.1056/NEJM199903113401004
Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, 1391, 10.1056/NEJMoa040446
Walsh, 2002, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, N Engl J Med, 346, 225, 10.1056/NEJM200201243460403
Pittet, 1994, Candida colonization and subsequent infections in critically ill surgical patients, Ann Surg, 220, 751, 10.1097/00000658-199412000-00008
Wey, 1989, Risk factors for hospital-acquired candidemia: a matched case-control study, Arch Intern Med, 149, 2349, 10.1001/archinte.1989.00390100145030
Calandra, 1989, Clinical significance of Candida isolated from peritoneum in surgical patients, Lancet, 2, 1437, 10.1016/S0140-6736(89)92043-6
Blumberg, 2001, Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey, Clin Infect Dis, 33, 177, 10.1086/321811
Puzniak, 2004, Has the epidemiology of nosocomial candidemia changed?, Infect Control Hosp Epidemiol, 25, 628, 10.1086/502452
Leleu, 2002, Systemic candidiasis in intensive care units: a multicenter, matched-cohort study, J Crit Care, 17, 168, 10.1053/jcrc.2002.35815
Sandven, 2001, Yeast colonization in surgical patients with intra-abdominal perforations, Eur J Clin Microbiol Infect Dis, 20, 475, 10.1007/s100960100531
Leon, 2006, A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization, Crit Care Med, 34, 730, 10.1097/01.CCM.0000202208.37364.7D
Paphitou, 2005, Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials, Med Mycol, 43, 235, 10.1080/13693780410001731619
Ostrosky-Zeichner, 2007, Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting, Eur J Clin Microbiol Infect Dis, 26, 271, 10.1007/s10096-007-0270-z
Sendid, 2004, Increased sensitivity of mannanemia detection tests by joint detection of α- and β-linked oligomannosides during experimental and human systemic candidiasis, J Clin Microbiol, 42, 164, 10.1128/JCM.42.1.164-171.2004
Ostrosky-Zeichner, 2005, Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans, Clin Infect Dis, 41, 654, 10.1086/432470
Obayashi, 2008, Reappraisal of the serum (1→3)-β-D-glucan assay for the diagnosis of invasive fungal infections: a study basd on autopsy cases from 6 years, Clin Infect Dis, 46, 1864, 10.1086/588295
Odabasi, 2004, Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome, Clin Infect Dis, 39, 199, 10.1086/421944
McMullen, 2008, A prospective clinical trial of a real-time PCR assay for the diagnosis of candidemia in nonneutropenic, critically ill adults, Clin Infect Dis, 46, 890, 10.1086/528690
Piarroux, 2004, Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients, Crit Care Med, 32, 2443, 10.1097/01.CCM.0000147726.62304.7F
Shan, 2006, Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery, World J Surg, 30, 119, 10.1007/s00268-005-7807-z
Schuster, 2008, Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial, Ann Intern Med, 149, 83, 10.7326/0003-4819-149-2-200807150-00004
Hughes, 2002, 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 34, 730, 10.1086/339215
Pizzo, 1982, Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia, Am J Med, 72, 101, 10.1016/0002-9343(82)90594-0
Empiric antifungal therapy in febrile granulocytopenic patients, 1989, EORTC International Antimicrobial Therapy Cooperative Group, Am J Med, 86, 668
Caillot, 1997, Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery, J Clin Oncol, 15, 139, 10.1200/JCO.1997.15.1.139
Caillot, 2001, Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia, J Clin Oncol, 19, 253, 10.1200/JCO.2001.19.1.253
Maertens, 2001, Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation, Blood, 97, 1604, 10.1182/blood.V97.6.1604
Prella, 2005, Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies, Diagn Microbiol Infect Dis, 51, 95, 10.1016/j.diagmicrobio.2004.08.015
Senn, 2008, 1,3-β-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia, Clin Infect Dis, 46, 878, 10.1086/527382
Maertens, 2005, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study, Clin Infect Dis, 41, 1242, 10.1086/496927
White, 1998, Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia, Clin Infect Dis, 27, 296, 10.1086/514672
Wingard, 2000, A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group, Clin Infect Dis, 31, 1155, 10.1086/317451
Winston, 2000, A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer, Am J Med, 108, 282, 10.1016/S0002-9343(99)00457-X
Malik, 1998, A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia, Am J Med, 105, 478, 10.1016/S0002-9343(98)00326-X
Viscoli, 1996, Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial, Eur J Cancer, 32A, 814, 10.1016/0959-8049(95)00619-2
Boogaerts, 2001, Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial, Ann Intern Med, 135, 412, 10.7326/0003-4819-135-6-200109180-00010
Ullmann, 2007, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med, 356, 335, 10.1056/NEJMoa061098
Cornely, 2007, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N Engl J Med, 356, 348, 10.1056/NEJMoa061094
Van Burik, 2004, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation, Clin Infect Dis, 39, 1407, 10.1086/422312
Tambyah, 2000, Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients, Arch Intern Med, 160, 678
Kauffman, 2000, Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group, Clin Infect Dis, 30, 14, 10.1086/313583
Jacobs, 1994, Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections, Clin Infect Dis, 18, 313, 10.1093/clinids/18.3.313
Kobayashi, 2004, Candiduria in hospital patients: a study prospective, Mycopathologia, 158, 49, 10.1023/B:MYCO.0000038436.51918.d9
Alvarez-Lerma, 2003, Candiduria in critically ill patients admitted to intensive care medical units, Intensive Care Med, 29, 1069, 10.1007/s00134-003-1807-y
van Etten, 1993, Efficacies of amphotericin B-desoxycholate (fungizone), liposomal amphotericin B (ambisome), and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice, J Antimicrob Chemother, 32, 723, 10.1093/jac/32.5.723
Abruzzo, 2000, Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice, Antimicrob Agents Chemother, 44, 2310, 10.1128/AAC.44.9.2310-2318.2000
Sobel, 2007, Caspofungin in the treatment of symptomatic candiduria, Clin Infect Dis, 44, e46, 10.1086/510432
Wise, 2006, How to diagnose and treat fungal infections in chronic prostatitis, Curr Urol Rep, 7, 320, 10.1007/s11934-996-0012-2
Bartkowski, 1988, Emphysematous prostatitis and cystitis secondary to Candida albicans, J Urol, 139, 1063, 10.1016/S0022-5347(17)42774-1
Jenkin, 1998, Candidal epididymo-orchitis: case report and review, Clin Infect Dis, 26, 942, 10.1086/513937
Chung, 2001, Successfully treated renal fungal ball with continuous irrigation of fluconazole, J Urol, 166, 1835, 10.1016/S0022-5347(05)65693-5
Bartone, 1988, The role of percutaneous nephrostomy in the management of obstructing candidiasis of the urinary tract in infants, J Urol, 140, 338, 10.1016/S0022-5347(17)41597-7
Shih, 2005, Percutaneous extraction of bilateral renal mycetomas in premature infant using mechanical thrombectomy device, Urology, 65, 1226, 10.1016/j.urology.2004.12.008
Babu, 2004, Renal fungal balls and pelvi-ureteric junction obstruction in a very low birth weight infant: treatment with streptokinase, Pediatr Surg Int, 20, 804, 10.1007/s00383-004-1301-9
Chitale, 2004, Endoscopic management of renal candidiasis, J Endourol, 18, 865, 10.1089/end.2004.18.865
Sobel, 1998, Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations, Am J Obstet Gynecol, 178, 203, 10.1016/S0002-9378(98)80001-X
Reef, 1995, Treatment options for vulvovaginal candidiasis, 1993, Clin Infect Dis, 20, 80, 10.1093/clinids/20.Supplement_1.S80
Watson, 2002, Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review, Bjog, 109, 85, 10.1111/j.1471-0528.2002.01142.x
Sobel, 2003, Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine, Am J Obstet Gynecol, 189, 1297, 10.1067/S0002-9378(03)00726-9
Sobel, 1996, Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus, Clin Infect Dis, 22, 726, 10.1093/clinids/22.4.726
Sobel, 2004, Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis, N Engl J Med, 351, 876, 10.1056/NEJMoa033114
Thaler, 1988, Hepatic candidiasis in cancer patients: the evolving picture of the syndrome, Ann Intern Med, 108, 88, 10.7326/0003-4819-108-1-88
Walsh, 1995, Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia, Cancer, 76, 2357, 10.1002/1097-0142(19951201)76:11<2357::AID-CNCR2820761126>3.0.CO;2-H
Gokhale, 1993, Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report, J Cancer Res Clin Oncol, 119, 569, 10.1007/BF01372718
Anaissie, 1991, Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy, Am J Med, 91, 142, 10.1016/0002-9343(91)90006-J
Kauffman, 1991, Hepatosplenic candidiasis: successful treatment with fluconazole, Am J Med, 91, 137, 10.1016/0002-9343(91)90005-I
Sora, 2002, Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B, Clin Infect Dis, 35, 1135, 10.1086/343748
Ostrosky-Zeichner, 2003, Voriconazole salvage treatment of invasive candidiasis, Eur J Clin Microbiol Infect Dis, 22, 651, 10.1007/s10096-003-1014-3
Legrand, 2008, Adjuvant corticosteroid therapy for chronic disseminated candidiasis, Clin Infect Dis, 46, 696, 10.1086/527390
Hendrickx, 2001, Candidal vertebral osteomyelitis: report of 6 patients, and a review, Clin Infect Dis, 32, 527, 10.1086/318714
Miller, 2001, Vertebral osteomyelitis due to Candida species: case report and literature review, Clin Infect Dis, 33, 523, 10.1086/322634
Hennequin, 1996, Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature, Clin Infect Dis, 23, 176, 10.1093/clinids/23.1.176
Malani, 2002, Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy, Clin Infect Dis, 35, 1316, 10.1086/344192
Sugar, 1990, Successful treatment of Candida osteomyelitis with fluconazole: a noncomparative study of two patients, Diagn Microbiol Infect Dis, 13, 517, 10.1016/0732-8893(90)90084-9
Dan, 1994, Failure of fluconazole therapy for sternal osteomyelitis due to Candida albicans, Clin Infect Dis, 18, 126, 10.1093/clinids/18.1.126
Petrikkos, 2001, Case report: successful treatment of two cases of post-surgical sternal osteomyelitis, due to Candida krusei and Candida albicans, respectively, with high doses of triazoles (fluconazole, itraconazole), Mycoses, 44, 422, 10.1046/j.1439-0507.2001.00673.x
Legout, 2006, Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient, Scand J Infect Dis, 38, 728, 10.1080/00365540500447192
Marra, 2001, Amphotericin B-loaded bone cement to treat osteomyelitis caused by Candida albicans, Can J Surg, 44, 383
Clancy, 1997, Candidal mediastinitis: an emerging clinical entity, Clin Infect Dis, 25, 608, 10.1086/513770
Harris, 2000, Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases, Pediatr Emerg Care, 16, 249, 10.1097/00006565-200008000-00008
Weigl, 2000, Candida arthritis in a premature infant treated successfully with oral fluconazole for six months, Ann Acad Med Singapore, 29, 253
Sim, 2005, Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin, Hong Kong Med J, 11, 120
Merrer, 2001, Candida albicans prosthetic arthritis treated with fluconazole alone, J Infect, 42, 208, 10.1053/jinf.2001.0819
Tunkel, 1993, Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature, Am J Med, 94, 100, 10.1016/0002-9343(93)90127-B
Sanchez-Portocarrero, 2000, The central nervous system and infection by Candida species, Diagn Microbiol Infect Dis, 37, 169, 10.1016/S0732-8893(00)00140-1
Nguyen, 1995, Meningitis caused by Candida species: an emerging problem in neurosurgical patients, Clin Infect Dis, 21, 323, 10.1093/clinids/21.2.323
Sanchez-Portocarrero, 1994, Candida cerebrospinal fluid shunt infection: report of two new cases and review of the literature, Diagn Microbiol Infect Dis, 20, 33, 10.1016/0732-8893(94)90016-7
Voice, 1994, Chronic candidal meningitis: an uncommon manifestation of candidiasis, Clin Infect Dis, 19, 60, 10.1093/clinids/19.1.60
Geers, 1999, Clinical significance of Candida species isolated from cerebrospinal fluid following neurosurgery, Clin Infect Dis, 28, 1139, 10.1086/514755
Casado, 1997, Candidal meningitis in HIV-infected patients: analysis of 14 cases, Clin Infect Dis, 25, 673, 10.1086/513746
Smego, 1984, Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis, Rev Infect Dis, 6, 791, 10.1093/clinids/6.6.791
Burgert, 1995, Candidal brain abscess associated with vascular invasion: a devastating complication of vascular catheter-related candidemia, Clin Infect Dis, 21, 202, 10.1093/clinids/21.1.202
Bonomo, 1996, Torulopsis (Candida) glabrata: a new pathogen found in spinal epidural abscess, Clin Infect Dis, 22, 588, 10.1093/clinids/22.3.588
Prabhu, 2004, Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis, Clin Infect Dis, 39, 1253, 10.1086/424449
Scarcella, 1998, Liposomal amphotericin B treatment for neonatal fungal infections, Pediatr Infect Dis J, 17, 146, 10.1097/00006454-199802000-00013
Gurses, 1996, Fluconazole monotherapy for candidal meningitis in a premature infant, Clin Infect Dis, 23, 645, 10.1093/clinids/23.3.645
Epelbaum, 1993, Failure of fluconazole treatment in Candida meningitis, J Pediatr, 123, 168, 10.1016/S0022-3476(05)81571-9
Marr, 1994, Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine, Clin Infect Dis, 19, 795, 10.1093/clinids/19.4.795
Torres, 2005, Posaconazole: a broad-spectrum triazole antifungal, Lancet Infect Dis, 5, 775, 10.1016/S1473-3099(05)70297-8
Liu, 2004, Refractory candidal meningitis in an immunocompromised patient cured by caspofungin, J Clin Microbiol, 42, 5950, 10.1128/JCM.42.12.5950-5953.2004
Axelrod, 1973, Intravitreal amphotericin B treatment of experimental fungal endophthalmitis, Am J Ophthalmol, 76, 584, 10.1016/0002-9394(73)90754-X
Edwards, 1974, Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis, Medicine Baltimore, 53, 47, 10.1097/00005792-197401000-00002
Parke, 1982, Endogenous endophthalmitis among patients with candidemia, Ophthalmology, 89, 789, 10.1016/S0161-6420(82)34722-3
McQuillen, 1992, Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis, Clin Infect Dis, 14, 472, 10.1093/clinids/14.2.472
Essman, 1997, Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis, Ophthalmic Surg Lasers, 28, 185, 10.3928/1542-8877-19970301-03
Akler, 1995, Use of fluconazole in the treatment of candidal endophthalmitis, Clin Infect Dis, 20, 657, 10.1093/clinids/20.3.657
Breit, 2005, Management of endogenous fungal endophthalmitis with voriconazole and caspofungin, Am J Ophthalmol, 139, 135, 10.1016/j.ajo.2004.08.077
Goldblum, 2002, Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model, Antimicrob Agents Chemother, 46, 3719, 10.1128/AAC.46.12.3719-3723.2002
Darling, 2000, Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC), J Infect, 40, 92, 10.1053/jinf.1999.0605
Thiel, 2007, Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis, Antimicrob Agents Chemother, 51, 239, 10.1128/AAC.00762-06
Hidalgo, 2000, Fungal endophthalmitis diagnosis by detection of Candida albicans DNA in intraocular fluid by use of a species-specific polymerase chain reaction assay, J Infect Dis, 181, 1198, 10.1086/315333
Venditti, 1992, Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis, Clin Infect Dis, 14, 422, 10.1093/clinids/14.2.422
Czwerwiec, 1993, Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis, Am J Med, 94, 545, 10.1016/0002-9343(93)90092-4
Nguyen, 1996, Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature, Clin Infect Dis, 22, 262, 10.1093/clinids/22.2.262
Lejko-Zupanc, 1997, A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone, J Infect, 35, 81, 10.1016/S0163-4453(97)91145-2
Melamed, 2000, Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome), Scand J Infect Dis, 32, 86, 10.1080/00365540050164281
Aaron, 2003, Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis, Scand J Infect Dis, 35, 351, 10.1080/00365540310008357
Jimenez-Exposito, 2004, Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment, Clin Infect Dis, 39, e70, 10.1086/424018
Westling, 2005, Candida albicans tricuspid valve endocarditis in an intravenous drug addict: successful treatment with fluconazole, Scand J Infect Dis, 37, 310, 10.1080/00365540410021207-1
Rajendram, 2005, Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement, Clin Infect Dis, 40, e72, 10.1086/429322
Steinbach, 2005, A meta-analysis of medical versus surgical therapy for Candida endocarditis, J Infect, 51, 230, 10.1016/j.jinf.2004.10.016
Ellis, 2001, Fungal endocarditis: evidence in the world literature, 1965–1995, Clin Infect Dis, 32, 50, 10.1086/317550
Muehrcke, 1995, Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis, Ann Thorac Surg, 60, 538, 10.1016/0003-4975(95)00469-2
Mayayo, 1996, Fungal endocarditis in premature infants: case report and review, Clin Infect Dis, 22, 366, 10.1093/clinids/22.2.366
Levy, 2006, Candida endocarditis in neonates: report of five cases and review of the literature, Mycoses, 49, 43, 10.1111/j.1439-0507.2005.01183.x
Noyola, 2001, Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia, Clin Infect Dis, 32, 1018, 10.1086/319601
Mrowczynski, 2004, Caspofungin for Candida endocarditis, Pediatr Infect Dis J, 23, 376, 10.1097/00006454-200404000-00029
Moudgal, 2005, Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis, Antimicrob Agents Chemother, 49, 767, 10.1128/AAC.49.2.767-769.2005
Bacak, 2006, Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature, J Infect, 53, e11, 10.1016/j.jinf.2005.10.003
Lye, 2005, Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review, Eur J Clin Microbiol Infect Dis, 24, 753, 10.1007/s10096-005-0038-2
Lopez-Ciudad, 2006, Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole, BMC Infect Dis, 6, 73, 10.1186/1471-2334-6-73
Cornely, 2007, Caspofungin for the treatment of less common forms of invasive candidiasis, J Antimicrob Chemother, 60, 363, 10.1093/jac/dkm169
Baddley, 2008, Candida infective endocarditis, Eur J Clin Microbiol Infect Dis, 27, 519, 10.1007/s10096-008-0466-x
Penk, 1999, Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants, Mycoses, 42, 91, 10.1111/j.1439-0507.1999.tb00021.x
Schrank, 1995, Purulent pericarditis caused by Candida species: case report and review, Clin Infect Dis, 21, 182, 10.1093/clinids/21.1.182
Neughebauer, 2002, Constrictive pericarditis caused by Candida glabrata in an immunocompetent patient: case report and review of literature, Scand J Infect Dis, 34, 615, 10.1080/00365540210147615
Azizov, 2002, Fungal myocarditis in deep visceral candidiasis [in Russian], Kardiologiia, 42, 56
Friedland, 1996, Peripheral thrombophlebitis caused by Candida, Pediatr Infect Dis J, 15, 375, 10.1097/00006454-199604000-00018
Benoit, 1998, Management of candidal thrombophlebitis of the central veins: case report and review, Clin Infect Dis, 26, 393, 10.1086/516319
Pan, 2005, Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents, Med Mycol, 43, 731, 10.1080/13693780500302593
Joly, 1997, Pacemaker endocarditis due to Candida albicans: case report and review, Clin Infect Dis, 25, 1359, 10.1086/516125
Roger, 2000, Medical treatment of a pacemaker endocarditis due to Candida albicans and to Candida glabrata, J Infect, 41, 176, 10.1053/jinf.2000.0640
Brown, 2001, Implantable cardioverter-defibrillator endocarditis secondary to Candida albicans, Am J Med Sci, 322, 160, 10.1097/00000441-200109000-00010
Hindupur, 2005, Septic shock induced from an implantable cardioverter-defibrillator lead-associated Candida albicans vegetation, J Interv Card Electrophysiol, 14, 55, 10.1007/s10840-005-3246-x
Benjamin, 2006, Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months, Pediatrics, 117, 84, 10.1542/peds.2004-2292
Driessen, 1996, Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial, Pediatr Infect Dis J, 15, 1107, 10.1097/00006454-199612000-00011
Linder, 2003, Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations, J Antimicrob Chemother, 52, 663, 10.1093/jac/dkg419
Wurthwein, 2005, Population pharmacokinetics of amphotericin B lipid complex in neonates, Antimicrob Agents Chemother, 49, 5092, 10.1128/AAC.49.12.5092-5098.2005
Kaufman, 2001, Fluconazole prophylaxis against fungal colonization and infection in preterm infants, N Engl J Med, 345, 1660, 10.1056/NEJMoa010494
Manzoni, 2007, A multicenter, randomized trial of prophylactic fluconazole in preterm neonates, N Engl J Med, 356, 2483, 10.1056/NEJMoa065733
Benjamin, 2006, Infection in late preterm infants, Clin Perinatol, 33, 871, 10.1016/j.clp.2006.09.005
Masur, 1977, Pulmonary disease caused by Candida species, Am J Med, 63, 914, 10.1016/0002-9343(77)90546-0
Kontoyiannis, 2002, Pulmonary candidiasis in patients with cancer: an autopsy study, Clin Infect Dis, 34, 400, 10.1086/338404
Rello, 1998, The role of Candida sp. isolated from bronchoscopic samples in nonneutropenic patients, Chest, 114, 146, 10.1378/chest.114.1.146
el-Ebiary, 1997, Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients: an immediate postmortem histologic study, Am J Respir Crit Care Med, 156, 583, 10.1164/ajrccm.156.2.9612023
Wood, 2006, Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients, Intensive Care Med, 32, 599, 10.1007/s00134-005-0065-6
Sangeorzan, 1994, Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance, Am J Med, 97, 339, 10.1016/0002-9343(94)90300-X
Bonacini, 1991, The causes of esophageal symptoms in human immunodeficiency virus infection: a prospective study of 110 patients, Arch Intern Med, 151, 1567, 10.1001/archinte.1991.00400080067012
Phillips, 1996, Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility, AIDS, 10, 1369, 10.1097/00002030-199610000-00009
Pons, 1993, Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group, J Acquir Immune Defic Syndr, 6, 1311
Finlay, 1996, A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours, Br J Oral Maxillofac Surg, 34, 23, 10.1016/S0266-4356(96)90130-8
Cartledge, 1997, Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis, J Clin Pathol, 50, 477, 10.1136/jcp.50.6.477
Queiroz-Telles, 2001, Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients, Braz J Infect Dis, 5, 60, 10.1590/S1413-86702001000200003
Phillips, 1998, A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS, Clin Infect Dis, 26, 1368, 10.1086/516342
Vazquez, 2006, A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS, Clin Infect Dis, 42, 1179, 10.1086/501457
Havlir, 1998, Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS, Clin Infect Dis, 27, 1369, 10.1086/515018
Meunier, 1994, Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients, Eur J Cancer B Oral Oncol, 30B, 196, 10.1016/0964-1955(94)90091-4
Philpott-Howard, 1993, Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group, J Antimicrob Chemother, 31, 973, 10.1093/jac/31.6.973
Smith, 1999, A randomised, double-blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection, Int J Clin Pract, 53, 349, 10.1111/j.1742-1241.1999.tb11744.x
Saag, 1999, Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients, AIDS Res Hum Retroviruses, 15, 1413, 10.1089/088922299309919
Skiest, 2007, Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection, Clin Infect Dis, 44, 607, 10.1086/511039
Hegener, 1998, Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS, AIDS, 12, 2227
Dewsnup, 1994, Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole, J Med Vet Mycol, 32, 389, 10.1080/02681219480000511
Vazquez, 2000, Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study, HIV Clin Trials, 1, 23, 10.1310/LF5T-WYY7-0U3E-G8BQ
Bodasing, 2002, Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient, J Antimicrob Chemother, 50, 765, 10.1093/jac/dkf206
Wilcox, 1996, Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms, Gastroenterology, 110, 1803, 10.1053/gast.1996.v110.pm8964406
Barbaro, 1996, Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome, Gastroenterology, 111, 1169, 10.1053/gast.1996.v111.pm8898629
Wilcox, 1997, A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis, J Infect Dis, 176, 227, 10.1086/514028
Ally, 2001, A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients, Clin Infect Dis, 33, 1447, 10.1086/322653
Martins, 1998, Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients, Clin Infect Dis, 27, 1291, 10.1086/515006
Kirkpatrick, 1979, Mucocutaneous candidiasis and thymoma, Am J Med, 66, 939, 10.1016/0002-9343(79)90448-0
Kamai, 2004, Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis, Microbiol Immunol, 48, 937, 10.1111/j.1348-0421.2004.tb03623.x
Hadley, 1995, Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression, Transplantation, 59, 851, 10.1097/00007890-199503000-00009
Karchmer, 1995, Fungal infections complicating orthotopic liver transplantation, Trans Am Clin Climatol Assoc, 106, 38
Kung, 1995, Fluconazole prophylaxis for high-risk liver transplant recipients, Lancet, 345, 1234, 10.1016/S0140-6736(95)92014-5
Tollemar, 1995, Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo-controlled study, Transplantation, 59, 45, 10.1097/00007890-199501150-00009
Lumbreras, 1996, Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation, J Infect Dis, 174, 583, 10.1093/infdis/174.3.583
Winston, 1999, Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial, Ann Intern Med, 131, 729, 10.7326/0003-4819-131-10-199911160-00003
Hadley, 2009, Outcomes of anifungal prophylaxisin high-risk liver transplant recients, Transpl Infect Dis, 11, 40, 10.1111/j.1399-3062.2008.00361.x
Benedetti, 1996, Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome, J Am Coll Surg, 183, 307
Guaraldi, 2005, Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients, Transplantation, 80, 1742, 10.1097/01.tp.0000185622.91708.57
Grossi, 2000, Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients, Transplantation, 70, 112
Ostrosky-Zeichner, 2004, Prophylaxis and treatment of invasive candidiasis in the intensive care setting, Eur J Clin Microbiol Infect Dis, 23, 739, 10.1007/s10096-004-1215-4
Garbino, 2002, Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination, Intensive Care Med, 28, 1708, 10.1007/s00134-002-1540-y
Pelz, 2001, Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients, Ann Surg, 233, 542, 10.1097/00000658-200104000-00010
Eggimann, 1999, Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients, Crit Care Med, 27, 1066, 10.1097/00003246-199906000-00019
Playford, 2006, Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials, J Antimicrob Chemother, 57, 628, 10.1093/jac/dki491
Shorr, 2005, Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis, Crit Care Med, 33, 1928, 10.1097/01.CCM.0000178352.14703.49
Bow, 2002, Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials, Cancer, 94, 3230, 10.1002/cncr.10610
Mattiuzzi, 2006, Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies, Antimicrob Agents Chemother, 50, 143, 10.1128/AAC.50.1.143-147.2006
Glasmacher, 2003, Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients, J Clin Oncol, 21, 4615, 10.1200/JCO.2003.04.052
Wingard, 2007, Results of a randomized, double-blind trial of fluconazole versus voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients, 49th American Society of Hematology Annual Meeting and Exposition